Association between antidepressant use during pregnancy and infants born small for gestational age

Canadian Journal of Psychiatry

Volumn 55, Issue 10, 2010, Pages 643-652

  Ramos, Élodie ^a   St André, Martin ^b,c   Bérard, Anick ^b,c  

^a PFIZER INC   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antidepressant exposure; Quebec pregnancy registry; Selective serotonin reuptake inhibitors; Small for gestational age; Tricyclics; Venlafaxine

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ARTICLE; BIRTH WEIGHT; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRENATAL EXPOSURE; RISK ASSESSMENT; RISK FACTOR; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT;

EID: 78049304351     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005501000     Document Type: Article

References (33)

1. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003;188(3):812-815. (Pubitemid 36332456)
2. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055-2061.
3. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015.
4. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158(4):312-316.
5. Kramer MS, Platt RW, Wen SW, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001;108(2):E35.
6. Malloy MH. Size for gestational age at birth: impact on risk for sudden infant death and other causes of death, USA 2002. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F473-F478.
7. Strauss RS. Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort. JAMA. 2000;283(5):625-632.
8. Kistner A, Jacobson SH, Celsi G, et al. IGFBP-1 levels in adult women born small for gestational age suggest insulin resistance in spite of normal BMI. J Intern Med. 2004;255(1):82-88.
9. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113(2):368-375.
10. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-1730.
11. Einarson A, Choi J, Einarson TR, et al. Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depress Anxiety. 2010;27:35-38.
12. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906.
13. World Health Organization. International Classification of Diseases. 9th rev. Geneva (CH): WHO; 1997.
14. Government of Quebec. Régie de l'assurance maladie du Québec. Statistiques Annuelles, 1997. Quebec City (QC): Government of Quebec; 1997.
15. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27. (Pubitemid 46303265)
16. Blais L, Beauchesne MF, Rey E, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax. 2007;62(4):320-328.
17. Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ. 2005;330(7485):230.
18. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64(4):496-509.
19. Ramos E, Oraichi D, Rey E, et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG. 2007;114(9):1055-1064. (Pubitemid 47247022)
20. Roy E, Haley N, Leclerc P, et al. Mortality in a cohort of street youth in Montreal. JAMA. 2004;292(5):569-574.
21. Blais L, Lemiere C, Menzies D, et al. Validity of asthma diagnoses recorded in the medical services database of Quebec. Pharmacoepidemiol Drug Saf. 2006;15(4):245-252.
22. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48(8):999-1009.
23. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15(11):1277-1282. (Pubitemid 30006767)
24. Dupont WD. Power calculations for matched case-control studies. Biometrics. 1988;44(4):1157-1168.
25. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.
26. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747.
27. Ahluwalia IB, Merritt R, Beck LF, et al. Multiple lifestyle and psychosocial risks and delivery of small for gestational age infants. Obstet Gynecol. 2001;97(5 Pt 1):649-656.
28. Thompson JM, Clark PM, Robinson E, et al. Risk factors for small-for-gestational-age babies: the Auckland Birthweight Collaborative Study. J Paediatr Child Health. 2001;37(4):369-375.
29. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol. 1992;45(10):1093-1099.
30. Burton GJ, Jaunaiux E. Maternal vascularisation of the human placenta: does the embryo develop in a hypoxic environment? Gynecol Obstet Fertil. 2001;29(7-8):503-508.
31. Morrison JL, Chien C, Riggs KW, et al. Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth. Pediatr Res. 2002;51(4):433-442. (Pubitemid 34267313)
32. De Jong van den Berg LT, Feenstra N, Sorensen HT, et al. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology. 1999;60(1):33-36.
33. Murphy JM, Olivier DC, Monson RR, et al. Depression and anxiety in relation to social status. A prospective epidemiologic study. Arch Gen Psychiatry. 1991;48(3):223-229.